India-based Cipla has partnered with UK’s S&D Pharma to launch affordable, high-quality alternatives in the Czech Republic and Slovakia.

Under the deal, Cipla will introduce its respiratory product portfolio in both the countries, while S&D Pharma will look after the physical distribution of all products, including respiratory products.

Cipla Europe head Frank Pieters said: "We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years."

"Cipla will launch the Salmeterol-Fluticasone fixed combination in both markets under the name Fullhale after the receipt of necessary approvals."

S&D Pharma CEO Daniel Straus added: "Through this collaboration, we have secured a competitive and varied product pipeline for the future and very much look forward to contributing to the future success of Cipla’s respiratory range."

Cipla will launch the Salmeterol-Fluticasone fixed combination in both markets under the name Fullhale after the receipt of necessary regulatory and reimbursement approvals.

Fullhale will be available in a pMDI with HFA propellant in two strengths, 120 doses of 25/125mcg salmeterol/fluticasone and 120 doses of 25/250mcg salmeterol/fluticasone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The combination is already available under the name Duohal in Europe, apart from Croatia.

Recently, Cipla launched this product in Germany under the name of Serroflo, while in Sweden as Salmeterol/Fluticasone Cipla.

Cipla produces around 2000 products in 65 therapeutic categories and has presence in about 170 countries, while S&D Pharma manages the promotion and distribution of their products in Central Europe.